Scholarlink

<p>Brain-derived neurotrophic factor (BDNF) has been implicated in cardiovascular disease. However, the role of BDNF in coronary slow flow phenomenon (CSFP) remains unclear. This study explored the relationship between serum mature BDNF (mBDNF) levels and thrombolysis-in-myocardial-infarction frame count (TFC) as a measure of CSFP. Serum mBDNF was measured in 125 patients (mean age 60.2 years, 57% women) with suspected coronary artery disease before undergoing coronary angiography. Based on the corrected TFC, 77 patients were categorized as having CSFP and 48 normal coronary flow (NCF). The relationship of mTFC (mTFC) and CSFP with serum mBDNF was analysed using multivariable linear and logistic regression. mTFC ranged from 15.9 to 68.5 and mBDNF from 13.2 to 60.6 ng/mL. Serum mBDNF was inversely correlated with mTFC (Spearman rho − 0.327, <i>P</i> &lt; 0.001) and reduced in CSFP (median 25.9 ng/mL IQR 20.6, 32.2 vs. 34.5 ng/mL IQR 27.4, 41.6, <i>P</i> &lt; 0.001). Multivariable linear and logistic regression analyses indicated that log<sub>2</sub>(mBDNF in ng/mL) has an inverse association with log<sub>2</sub>(mTFC) (coefficient − 0.332,95% CI -0.513, -0.151; <i>P</i> &lt; 0.001) and reduced odds of CSFP (odds ratio 0.188, 95% CI 0.062, 0.573; <i>P</i> = 0.003). This suggests that BDNF may serve as a biomarker of CSFP, and provides new insights into its pathophysiology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Relationship between serum mature brain-derived neurotrophic factor level and coronary slow flow phenomenon: a cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月29日

查看全文
  • Hongshan Zhang,
  • Alan Frederick Geater,
  • Virasakdi Chongsuvivatwong,
  • Guofu Zhu,
  • Yong Meng,
  • Wenxiang Duan,
  • Lijin Pu

摘要

Brain-derived neurotrophic factor (BDNF) has been implicated in cardiovascular disease. However, the role of BDNF in coronary slow flow phenomenon (CSFP) remains unclear. This study explored the relationship between serum mature BDNF (mBDNF) levels and thrombolysis-in-myocardial-infarction frame count (TFC) as a measure of CSFP. Serum mBDNF was measured in 125 patients (mean age 60.2 years, 57% women) with suspected coronary artery disease before undergoing coronary angiography. Based on the corrected TFC, 77 patients were categorized as having CSFP and 48 normal coronary flow (NCF). The relationship of mTFC (mTFC) and CSFP with serum mBDNF was analysed using multivariable linear and logistic regression. mTFC ranged from 15.9 to 68.5 and mBDNF from 13.2 to 60.6 ng/mL. Serum mBDNF was inversely correlated with mTFC (Spearman rho − 0.327, P < 0.001) and reduced in CSFP (median 25.9 ng/mL IQR 20.6, 32.2 vs. 34.5 ng/mL IQR 27.4, 41.6, P < 0.001). Multivariable linear and logistic regression analyses indicated that log2(mBDNF in ng/mL) has an inverse association with log2(mTFC) (coefficient − 0.332,95% CI -0.513, -0.151; P < 0.001) and reduced odds of CSFP (odds ratio 0.188, 95% CI 0.062, 0.573; P = 0.003). This suggests that BDNF may serve as a biomarker of CSFP, and provides new insights into its pathophysiology.